Search
Descriptor English: Kallikreins
Descriptor Spanish: Calicreínas
Descriptor calicreínas
Entry term(s) calicreína
cininogenasa
quininogenasa
Scope note: Enzimas proteolíticas de la familia de la serina endopeptidasa que se encuentran en la sangre y la orina normales. Específicamente, las calicreínas son vasodilatadoras e hipotensoras potentes, aumentan la permeabilidad vascular y afectan a la musculatura lisa. En los varones se utilizan como tratamiento de la infertilidad masculina. Se conocen tres formas, la CALICREÍNA PLASMÁTICA (EC 3.4.21.34), la CALICREÍNA TISULAR (EC 3.4.21.35) y el ANTÍGENO ESPECÍFICO DE LA PRÓSTATA (EC 3.4.21.77).
Descriptor Portuguese: Calicreínas
Descriptor French: Kallicréines
Entry term(s): Callicrein
Dilminal
Enzyme, Kinin-Forming
Kallidinogenase
Kalliginogenase
Kallikrein
Kallikrein A
Kallikrein B'
Kallikrein Light Chain
Kinin Forming Enzyme
Kinin-Forming Enzyme
Kininogenase
Light Chain, Kallikrein
Padutin
alpha Kallikrein
alpha-Kallikrein
beta Kallikrein
beta Kallikrein B
beta-Kallikrein
beta-Kallikrein B
Tree number(s): D08.811.277.656.300.760.442
D08.811.277.656.959.350.442
D12.776.124.125.597
D23.119.597
RDF Unique Identifier: https://id.nlm.nih.gov/mesh/D007610
Scope note: Proteolytic enzymes from the serine endopeptidase family found in normal blood and urine. Specifically, Kallikreins are potent vasodilators and hypotensives and increase vascular permeability and affect smooth muscle. They act as infertility agents in men. Three forms are recognized, PLASMA KALLIKREIN (EC 3.4.21.34), TISSUE KALLIKREIN (EC 3.4.21.35), and PROSTATE-SPECIFIC ANTIGEN (EC 3.4.21.77).
Annotation: /antag permitted but consider KALLIKREIN-TRYPSIN INACTIVATOR
Allowable Qualifiers: AD administration & dosage
AE adverse effects
AI antagonists & inhibitors
AN analysis
BI biosynthesis
BL blood
CF cerebrospinal fluid
CH chemistry
CL classification
CS chemical synthesis
DE drug effects
DF deficiency
EC economics
GE genetics
HI history
IM immunology
IP isolation & purification
ME metabolism
PD pharmacology
PH physiology
PK pharmacokinetics
PO poisoning
RE radiation effects
SD supply & distribution
ST standards
TO toxicity
TU therapeutic use
UL ultrastructure
UR urine
Pharm Action: Coagulants
Fertility Agents, Male
Registry Number: EC 3.4.21.-
Public MeSH Note: 2000; see KALLIKREIN 1963-1999
History Note: 2000(1963)
Related: Coagulants MeSH
DeCS ID: 23326
Unique ID: D007610
NLM Classification: QU 136
Documents indexed in the Virtual Health Library (VHL): Click here to access the VHL documents
Date Established: 2000/01/01
Date of Entry: 1999/01/01
Revision Date: 2009/07/06
Kallikreins - Preferred
Concept UI M0011897
Scope note Proteolytic enzymes from the serine endopeptidase family found in normal blood and urine. Specifically, Kallikreins are potent vasodilators and hypotensives and increase vascular permeability and affect smooth muscle. They act as infertility agents in men. Three forms are recognized, PLASMA KALLIKREIN (EC 3.4.21.34), TISSUE KALLIKREIN (EC 3.4.21.35), and PROSTATE-SPECIFIC ANTIGEN (EC 3.4.21.77).
Preferred term Kallikreins
Entry term(s) Callicrein
Enzyme, Kinin-Forming
Kallidinogenase
Kalliginogenase
Kallikrein
Kinin Forming Enzyme
Kinin-Forming Enzyme
Kininogenase
Kallikrein Light Chain - Narrower
Concept UI M0011902
Preferred term Kallikrein Light Chain
Entry term(s) Light Chain, Kallikrein
Padutin - Narrower
Concept UI M0332548
Preferred term Padutin
Kallikrein A - Narrower
Concept UI M0011898
Preferred term Kallikrein A
beta-Kallikrein - Narrower
Concept UI M0011895
Preferred term beta-Kallikrein
Entry term(s) beta Kallikrein
beta-Kallikrein B - Narrower
Concept UI M0011896
Preferred term beta-Kallikrein B
Entry term(s) beta Kallikrein B
Dilminal - Narrower
Concept UI M0332549
Preferred term Dilminal
Kallikrein B' - Narrower
Concept UI M0011899
Preferred term Kallikrein B'
alpha-Kallikrein - Narrower
Concept UI M0011894
Preferred term alpha-Kallikrein
Entry term(s) alpha Kallikrein



We want your feedback on the new DeCS / MeSH website

We invite you to complete a survey that will take no more than 3 minutes.


Go to survey